Delivering Superior Signal Clarity

On a mission to end reliance on mixed signals and reading between the lines, BioSig Technologies understands that greater clarity breeds opportunity for a new standard in cardiac care.

Learn More
Beyond the Status Quo

Beyond the Status Quo

As physician advocates, we develop technology that provides greater clarity and opens doors to ingenious treatment solutions for the most challenging arrhythmias. We collaborate with physicians, experts, and healthcare leaders to align on the advancements that can be realized in the field of electrophysiology.

We are driven by a commitment to provide innovative solutions that elevate the standard of care. Our engineers are constantly in search of what’s possible in signal acquisition and the field of electrophysiology, driving the evolution of our technology for the physicians we serve.

An Innovation in One of the Most Critical Areas of Electrophysiology

An Innovation in One of the Most Critical Areas of Electrophysiology

The PURE EP™ Platform applies a unique combination of hardware and software to accurately capture intracardiac signals with unprecedented clarity and precision. By viewing pure signals that are absent of saturation, interference, or noise from other medical equipment, physicians can respond to even the most complex cardiac arrhythmias with insight-based, highly targeted cardiac ablation procedures.

Discover the PURE EP™ Platform

MEETING THE NEED TO IMPROVE ARRHYTHMIA TREATMENT

Leveraging EGMs to Improve Efficacy, Safety of Ablation: A Physician’s Perspective

"If we improve the fidelity of our [signal] recordings, we can potentially improve the efficiency and safety of our procedures. In that respect, the PURE EP™ System is really a breath of fresh air in this field."

- Hicham El Masry, M.D. (Mayo Clinic, Arizona)
Leveraging EGMs to Improve Efficacy, Safety of Ablation Kansas City Heart Rhythm Symposium (KCHRS) 2022

Discover BioSig

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join Our Team

Company

BioSig is an advanced signal processing company delivering unmatched accuracy and precision to intracardiac signal visualization, and enhancing the treatment of arrhythmias.

Learn more about BioSig

Leadership

By uniting the diverse talents and collective experiences of industry experts, we are determined to break down barriers and go beyond our comfort zone in pursuit of unconventional solutions that advance medical technology and make a lasting impact.

Meet the leadership team

Careers

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join our team

Insights

With the superior, real-time visualization of arrhythmias, PURE EP™ is paving the way for personalized patient care and breakthrough innovations in the field of electrophysiology. View the latest cases, presentations, and papers.

Explore physician insights

News & Stories

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules


Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ('BioSig' or the 'Company') a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants. 

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules


Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) ('BioSig' or the 'Company') a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,996,922 shares of its common stock, Series A warrants to purchase up to 6,996,922 shares of common stock and Series B warrants to purchase up to 6,996,922 shares of common stock, at a purchase price of $0.3573 per share of common stock and associated warrants, in a registered direct offering priced at-the-market under Nasdaq rules. 

BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP


32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in 2018 Part of leadership team that grew Johnson & Johnson's original cardiology/electrophysiology business from $22M to $500M in 7 years

Sign Up for BioSig Updates Contact Us
x formerly known as twitter icon X formerly known as Twitter
linkedin Facebook